P2 - Poster Session II

Event Time: Monday April 24, 2017 8:30 am to 7:00 pm
Topic(s): Aging, Dementia, Cognitive, and Behavioral Neurology, Cerebrovascular Disease and Interventional Neurology, Epilepsy/Clinical Neurophysiology (EEG), General Neurology, Headache, Infectious Disease, Movement Disorders, MS and CNS Inflammatory Disease, Neuromuscular and Clinical Neurophysiology (EMG), Practice, Policy, and Ethics, Research Methodology, Education, and History
Director(s):
Description: A series of thematic abstract presentations in poster format presented Sunday through Friday with evening stand-by times for authors. The specific stand-by time for this session is 5:30 pm to 7:00 pm.
Completion Message:
CME Credits: 0
Core Competencies:

Abstract Presenters

Movement Disorders: Huntington's Disease, Chorea, and Tardive Dyskinesia
Start Time Pub. Title Presenter
5:30 PM 001 Targeting sphingosine-1-phosphate lyase is neuroprotective in a neuron model of Huntington’s disease Erin Furr-Stimming, MD
Disclosure:
Dr. Furr-Stimming has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, FROG design as a consultant. Dr. Furr-Stimming has received research support from Teva, CHDI foundation, PPD.

5:30 PM 002 Behavioral Changes on the UCSD Huntington’s Disease Behavioral Questionnaire (HD-BQ) Distinguish Patients Transitioning to Manifest Huntington’s disease (HD) Jody Corey-Bloom, MD, PhD
Disclosure:
Dr. Corey-Bloom has received research support from Teva, Vaccinex, HSG, and CHDI.

5:30 PM 003 The Balance Tracking System (BTrackS™) Measures Disease Progression and Fall Risk in Huntington's Disease Sungmee Park
Disclosure:
Dr. Park has nothing to disclose.

5:30 PM 004 Assessment of capacity to consent in a Huntington disease clinical trial: implications for future clinical trial design in neurodegenerative disease populations Claudia Testa, MD, PhD
Disclosure:
Dr. Testa has research support fom Huntington Study Group Ltd and Auspex Pharmaceuticals.

5:30 PM 005 Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results from the Phase II, Double-blind, Placebo-controlled, Dose-Ranging Study, Pride-HD Spyros Papapetropoulos, MD, PhD
Disclosure:
Dr. Kieburtz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Research grants from the National Institutes of Health, the Michael J. Fox Foundation, Medivation, and Neurosearch. Consultant to the United States Food and Drug Administration, Veterans Administration, and National Institutes of Health, AbbVie, Acorda, A.

5:30 PM 006 Multicenter, Randomized, Double-blind, Placebo-controlled Phase 1b/2a Studies of WVE-120101 and WVE-120102 in Patients with Huntington’s Disease Steven Hersch, MD, PhD
Disclosure:
Wave Life Sciences: Consulting Pfizer: Consulting Roche: Consulting Voyager Therapeutics: Consulting. Wave Life Sciences: Laboratory Research Voyager Therapeutics: Laboratory Research.

5:30 PM 007 When DBS can be of benefit in Huntington’s disease Jessica Karl, PA
Disclosure:
Dr. Karl has nothing to disclose.

5:30 PM 008 Tetrabenazine and olanzapine in management of Huntington disease: comparative retrospective analysis of data from the worldwide observational study Enroll-HD Yury Seliverstov
Disclosure:
Dr. Seliverstov has nothing to disclose.

5:30 PM 009 Tetrabenazine Use in Patients With Huntington’s Disease (HD) Chorea Victor W. Sung, MD
Disclosure:
Dr. Sung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva.

5:30 PM 010 Late-Onset Huntington Disease: Clinical Cases with Intermediate CAG Repeat Expansions Dana McDermott, DO
Disclosure:
Dr. McDermott has nothing to disclose.

5:30 PM 011 Effect of Pridopidine on Total Functional Capacity (TFC) in Huntington Disease (HD): A Comparison of Open-HART Subjects with Historical Placebo Controls Andrew McGarry, MD
Disclosure:
Pimvanserin speaker bureau. Research funding from Teva pharmaceuticals.

5:30 PM 012 Central cognitive processing speed is an early marker of Huntington's disease (HD) onset Ajay Nathan
Disclosure:
Dr. Nathan has nothing to disclose.

5:30 PM 013 Implementation and Validation of a Biometric Solution for Remote Monitoring of Motor Symptoms in Patients with Huntington’s Disease in a Phase II Clinical Trial Spyros Papapetropoulos
Disclosure:
Dr. Papapetropoulos has received personal compensation for activities with Teva Pharmaceuticals as an employee.

5:30 PM 014 Epidemiology of Juvenile Huntington’s Disease in the United States Anh-Thu Ngo Vu, MD
Disclosure:
Dr. Vu has nothing to disclose.

5:30 PM 015 Huntington Disease-like 2: a case series of six patients Victor Calil da Silveira, MBBS
Disclosure:
Dr. Calil da Silveira has nothing to disclose.

5:30 PM 016 Deutetrabenazine Treatment Response by Concomitant Dopamine-Receptor Antagonists in the Phase III, Randomized, Double-Blind, Placebo-Controlled AIM-TD Trial in Tardive Dyskinesia (TD) Joohi Jimenez-Shahed
Disclosure:
Dr. Jimenez-Shahed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, St. Jude Medical, Medtronic. Dr. Jimenez-Shahed has received research support from Avid Radiopharmaceuticals, Acadia Pharmaceuticals, St. Jude Medical, Biotie, Michael J. Fox Foundation.

5:30 PM 017 Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of Long-Term Exposure Data from Three Studies Gary Remington
Disclosure:
Dr. Remington has received research support from Novartis.

5:30 PM 018 Estimation of Epidemiology of Tardive Dyskinesia in the United States Amit Dhir
Disclosure:
Dr. Dhir has received personal compensation for activities with SmartAnalyst, Inc. as an employee.

5:30 PM 019 Hyperglycemic chorea/hemiballism ascertained at a large medical center over 15 years: Frequency & characteristics Conor Ryan, MD
Disclosure:
Dr. Ryan has nothing to disclose.

5:30 PM 020 Deutetrabenazine is Associated with an Improvement in Involuntary Movements in Patients With Tardive Dyskinesia (TD) as Seen by the High Proportion of Responders to Deutetrabenazine Treatment in the AIM-TD Study Joohi Jimenez-Shahed
Disclosure:
Dr. Jimenez-Shahed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, St. Jude Medical, Medtronic. Dr. Jimenez-Shahed has received research support from Avid Radiopharmaceuticals, Acadia Pharmaceuticals, St. Jude Medical, Biotie, Michael J. Fox Foundation.

5:30 PM 021 Reducing Variability in the Measurement of Chorea Samuel Frank, MD
Disclosure:
Dr. Frank has received research support from Teva Pharmaceutical Industries.

5:30 PM 022 Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis in Chorea-Acanthocytosis Karin Mente, MD
Disclosure:
Dr. Mente has nothing to disclose.

5:30 PM 023 A Rare Case of Paraneoplastic Chorea Andrea Stoner, DO
Disclosure:
Dr. Stoner has nothing to disclose.

5:30 PM 024 An unusual case of hemichorea in a woman with newly discovered renal cell carcinoma and inconclusive LGI-1 antibody Kalea Colletta, DO
Disclosure:
Dr. Colletta has nothing to disclose.

5:30 PM 025 Pharmacologic Characteristics of Valbenazine (NBI-98854) and its Metabolites Dimitri Grigoriadis
Disclosure:
Dr. Grigoriadis has received personal compensation for activities with Neurocrine Biosciences, Inc. as an employee.

Movement Disorders: Other I
Start Time Pub. Title Presenter
5:30 PM 026 Efficacy and Safety of a Novel Copper Modulating Agent (WTX-101) for Wilson Disease: Results of a Phase 2, Multi-Center, Open Label Study Danny Bega
Disclosure:
Dr. Bega has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals, and Acadia Pharmaceuticals. Dr. Bega has received personal compensation in an editorial capacity for British Medical Journal.

5:30 PM 027 Correspondence between MRI borders of the subthalamic nucleus and its electrophysiological borders: a comparison study using intraoperative CT. Sander Bus
Disclosure:
Dr. Bus has nothing to disclose.

5:30 PM 028 Basal Ganglia and Limbic Striatal Regions are Differentially Affected by Pramipexole: D3 receptor – Mediated Changes in Markers of Synaptic Strength Meagan Bailey, MD
Disclosure:
Dr. Bailey has nothing to disclose.

5:30 PM 029 Imaging Biomarkers of Delayed Sequelae in Mild Traumatic Brain Injury Nicole Reams
Disclosure:
AAN SCC honorarium, Consulting fees for expert witness......

History of Neurology
Start Time Pub. Title Presenter
5:30 PM 031 Da Costa’s Syndrome and Postural Tachycardia Syndrome: A rose by any other name? Kelsey Klaas
Disclosure:
Dr. Klaas has nothing to disclose.

5:30 PM 032 Trepanation procedures and outcomes: prehistoric Peru (c. 400 BC) to Modern Neurosurgery (early 20th century) David S. Kushner
Disclosure:
Dr. Kushner has nothing to disclose.

5:30 PM 033 Dr. Paula Coutinho's Seminal Contributions to the Understanding of Machado-Joseph′s Disease. Bruno Carniatto Marques Garcia
Disclosure:
Dr. Carniatto Marques Garcia has nothing to disclose.

5:30 PM 034 The Illustrated Mind Harry Sutherland-Foggio
Disclosure:
Dr. Sutherland-Foggio has nothing to disclose.

5:30 PM 035 The forgotten semiology: the evolution of neurological diagnosis Victor Calil da Silveira, MBBS
Disclosure:
Dr. Calil da Silveira has nothing to disclose.

5:30 PM 036 Serendipity & Neurology Yuan-Kai Lee
Disclosure:
Dr. Lee has nothing to disclose.

5:30 PM 037 William Hammond's perspective on the assassination of President Garfield Eric Prince, MD
Disclosure:
Dr. Prince has nothing to disclose.

5:30 PM 038 History of neuroimaging in Multiple Sclerosis: 1838-2016 Nicoletta Caputi
Disclosure:
Dr. Caputi has nothing to disclose.

5:30 PM 039 Religious and political conflicts could cause the incidence of conversion disorders in 17th century – the analysis of “The Anatomy of Melancholy” by Robert Burton. Joanna Bielewicz, PhD
Disclosure:
Dr. Bielewicz has nothing to disclose.

5:30 PM 040 Argyll Robertson and Spinal Myosis Jennifer Creed, MD, PhD
Disclosure:
Dr. Creed has nothing to disclose.

5:30 PM 041 The Influence of Social Science on the Nosology of Dementia Matthew Schelke
Disclosure:
Dr. Schelke has nothing to disclose.

5:30 PM 042 Alice In Wonderland Syndrome: A History Edward Fine, MD, FAAN
Disclosure:
Dr. Fine has nothing to disclose.

5:30 PM 043 The Evolutionary Saga of Corticosteriod in Myasthenia Gravis and What We Have Learnt From This… Sankar Bandyopadhyay
Disclosure:
Dr. Bandyopadhyay has nothing to disclose.

5:30 PM 044 On the History of Multiple Sclerosis and War Ahmed Z Obeidat, MD, PhD
Disclosure:
Dr. Obeidat has nothing to disclose.

5:30 PM 045 "Flaneur Neurologique" in Paris – A Neurological Guide to Pinpointing the Houses of Famous Neurologists in the Late XIX Century; Charcot and his Triumvirate of Favourite Pupils. Carlos Henrique Camargo
Disclosure:
Dr. Camargo has nothing to disclose.

5:30 PM 046 Remembering James Parkinson (1755-1824): His historic essay on the shaking palsy and his prodigious eclectic career as a "physician for all seasons" Alison Roby
Disclosure:
Dr. Roby has nothing to disclose.

5:30 PM 047 The Reflex Hammer: A Brief History of the Tool We Know and Love Daniella Sisniega
Disclosure:
Dr. Sisniega has nothing to disclose.

5:30 PM 048 Soul-searching in the Brain: Classical Antiquity to 17th Century Suraj Rajan, MD
Disclosure:
Dr. Rajan has nothing to disclose.

5:30 PM 049 Hitler′s Neuro-psychiatric Medley, an Un-ignorable War History for Neurologists. Sankar Bandyopadhyay, MD
Disclosure:
Dr. Bandyopadhyay has nothing to disclose.

5:30 PM 050 Marc Chagall′s L'homme A La Tete Renversee (Man With His Head Thrown Back) – An Artistic Depiction of Severe Retrocollis in Neurodegeneration with Brain Iron Accumulation Marlon Caeira
Disclosure:
Dr. Caeira has nothing to disclose.

5:30 PM 051 Historical Perspective of Cambodian Medicine with a focus on Neurology Sandeep Singh
Disclosure:
Dr. Singh has nothing to disclose.

Research Methodologies
Start Time Pub. Title Presenter
5:30 PM 052 Development of an Algorithm to Identify Multiple Sclerosis (MS) Disease Severity Based on Healthcare Costs in a US Administrative Claims Database Jacqueline Nicholas, MD
Disclosure:
Dr. Nicholas has nothing to disclose.

5:30 PM 053 Interactive sensory digital platform for upper limb sensory assessment in patients with multiple sclerosis Michal Greenberg-Abrahami
Disclosure:
Dr. Greenberg-Abrahami has nothing to disclose.

5:30 PM 055 Probable Rates vs. Self-Reported: Variances in Concussion Reporting and Extent of Education for High School Athletes Constance Johnson
Disclosure:
Dr. Johnson has nothing to disclose.

5:30 PM 056 Development and Validation of a Patient Centered Young Stroke Outcome Measure Tool Ravish Kothari, MD
Disclosure:
Dr. Kothari has nothing to disclose.

5:30 PM 057 Psychometric evaluation of quality of life measures in a three-arm, randomized, double-blind, placebo-controlled phase III study of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures (EXIST-3) Petrus de Vries
Disclosure:
Dr. de Vries has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis. Dr. de Vries has received research support from Novartis.

5:30 PM 058 Chiari I Malformation Common Data Element Project: The National Institute of Neurological Disorders and Stroke (NINDS) Chiari I Malformation Common Data Elements (CDE) Recommendations Version 1.0 Website Release Robin Feldman
Disclosure:
Dr. Feldman has nothing to disclose.

5:30 PM 059 Primary and secondary progressive MS subjects in clinical trials: Are they similar? Robert Fox, MD, FAAN
Disclosure:
Dr. Fox has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Received compensation for serving as consultant or speaker from Allozyne, Avanir, Biogen Idec, Novartis, Questcor, and Teva Pharmaceutical Industries. Dr. Fox has received research support from Biogen (clinical trial contracts) and Novartis (research study support)..

5:30 PM 060 A Common Data Language for Clinical Research Studies: The National Institute of Neurological Disorders and Stroke (NINDS) and American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) Cerebral Palsy Common Data Elements Version 1.0 Recommendations Robin Feldman
Disclosure:
Dr. Feldman has nothing to disclose.

5:30 PM 061 First Global Multifocal Motor Neuropathy (MMN) Quality of Life (QOL) Patient Survey Identifies Needs in Education and Treatment Jonathan Katz, MD
Disclosure:
Dr. Katz has nothing to disclose.

5:30 PM 062 The 10-Point Disability Scale in Multiple Sclerosis: Phase I Development and Planning study Ahmed Z Obeidat, MD, PhD
Disclosure:
Dr. Obeidat has nothing to disclose.

Practice, Policy, and Ethics II
Start Time Pub. Title Presenter
5:30 PM 063 Pilot for the Implementation of a Telemedicine Program (Home Video Visits) at an ALS Center of Excellence Samuel Maiser, MD
Disclosure:
Dr. Maiser has nothing to disclose.

5:30 PM 064 To Assess the Efficacy of Dr. Stroke Activation System in Optimization Door to Needle Time at Primary Stroke Center-A Quality Improvement Project Syed Abbas, MD
Disclosure:
Dr. Abbas has nothing to disclose.

5:30 PM 065 Addressing direct admission workflow through process mapping Kyle Rossi, MD
Disclosure:
Dr. Rossi has nothing to disclose.

5:30 PM 066 Misinformation on the internet means public health organizations need to reassess their Zika policies Anand Venkatraman
Disclosure:
Dr. Venkatraman has nothing to disclose.

5:30 PM 067 A multi-faceted approach to reduce no show rates in an outpatient specialty clinic Tracie Caller
Disclosure:
Dr. Caller has received personal compensation for activities with Medlick for authoring and revising an article.

5:30 PM 068 Quality of Stroke Care Among Ischemic Stroke Patients Discharged from Non-Neurology Services Elena Gibson
Disclosure:
Dr. Gibson has nothing to disclose.

5:30 PM 069 Which patients are deemed not appropriate for neurologic consultation, and what happens to them? Roland Brilla, MD, MPH
Disclosure:
Dr. Weiss has nothing to disclose.

5:30 PM 070 Ethics of Medical Marijuana Use in Pediatric Epilepsy Alison Christy, MD, PhD
Disclosure:
Dr. Christy has nothing to disclose.

MS and CNS Inflammatory Disease ePoster Session
Start Time Pub. Title Presenter
5:30 PM 071 Relevance of functional connectivity abnormalities to cognitive impairment in neuromyelitis optica spectrum disoder Filippo Savoldi
Disclosure:
Dr. Savoldi has nothing to disclose.

5:30 PM 072 The clinical profile of NMOSD in Australia and New Zealand Laura Clarke
Disclosure:
Dr. Clarke has nothing to disclose.

5:30 PM 073 The Effects of Natalizumab and Fingolimod on Clinical and MRI Measures in Relapsing Remitting Multiple Sclerosis: A Two-Year Comparative Study Paolo Preziosa, MD
Disclosure:
Dr. Preziosa has nothing to disclose.

5:30 PM 074 Elsberg syndrome: A rarely recognized cause of cauda equina syndrome and lower thoracic myelitis Filippo Savoldi
Disclosure:
Dr. Savoldi has nothing to disclose.

5:30 PM 075 Upper gastrointestinal lymphoma: an emerging late complication of natalizumab therapy? Emily Watson
Disclosure:
Dr. Watson has nothing to disclose.

5:30 PM 076 Lumbosacral Radiculomyelopathy- a rare presentation in an established case of Neuromyelitis Optica Spectrum DIsorders Shweta Sapnar, MD
Disclosure:
Dr. Sapnar has nothing to disclose.

5:30 PM 077 Tissue-­?specific MRI features in the brainstem and corpus callosum of MS and NMOSD cohorts, compared to healthy control subjects Lisa Eunyoung Lee
Disclosure:
Dr. Lee has nothing to disclose.

5:30 PM 078 Neurologic Complications of IGG4 Related Disease: A Case Report Alison Walsh, MD
Disclosure:
Dr. Walsh has nothing to disclose.

5:30 PM 079 A challenging case of a AQP-4-seronegative, anti-MOG positive, NMOSD patient. Clementine Karageorgiou, MD
Disclosure:
Dr. Karageorgiou has nothing to disclose.

5:30 PM 080 Differential brainstem atrophy patterns in multiple sclerosis and neuromyelitis optica spectrum disorders among Hong Kong Chinese Chi Yan Lee, MD
Disclosure:
Dr. Lee has nothing to disclose.

Frontotemporal Dementia
Start Time Pub. Title Presenter
5:30 PM 081 Instrumental activities of daily living in clinical subtypes of frontotemporal dementia Negar Moheb
Disclosure:
Dr. Moheb has nothing to disclose.

5:30 PM 082 Rescue of Tau Phenotypes in Human iPSC-Derived Neuronal Models of Frontotemporal Degeneration with Experimental Therapeutics M. Catarina Silva
Disclosure:
Dr. Silva has received research support from AstraZeneca.

5:30 PM 083 Evaluation of quantitative EEG as a disease and treatment response biomarker in frontotemporal dementia Elena Ratti, MD
Disclosure:
Dr. Ratti has nothing to disclose.

5:30 PM 084 Structural and functional brain connectome architecture in early onset Alzheimer’s disease and the behavioral variant of frontotemporal dementia Massimo Filippi, MD
Disclosure:
Dr. Filippi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Merk-Serono, Novartis, Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in an editorial capacity for Journal of Neurology. Dr. Filippi has received research support from Biogen Idec, Novartis, Teva Pharmaceutical Industries.

5:30 PM 085 Cognitive reserve and TMEM106B genotype modulate brain damage in pre-symptomatic monogenic FTD: results from the GENFI study Enrico Premi
Disclosure:
Dr. Premi has nothing to disclose.

5:30 PM 087 Perfusion alterations reveal distinct patterns of early vulnerability to damage across the ALS-FTLD continuum Pilar M. Ferraro
Disclosure:
Dr. Ferraro has nothing to disclose.

5:30 PM 088 Characteristics and Progress on the Initial 209 Subjects in the Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) Protocol Bradley Boeve, MD
Disclosure:
Dr. Boeve has received research support from GE Heathcare and Axovant.

Aging and Dementia: Neuropathology
Start Time Pub. Title Presenter
5:30 PM 089 Neuropathological Basis of Apolipoprotein E Genotype on Psychosis in Alzheimer's Disease Julia Kim
Disclosure:
Dr. Kim has nothing to disclose.

5:30 PM 090 Globular Glial Tauopathy (GGT): clinical-pathological study of two autopsied cases and review of the literature Takeshi Miura
Disclosure:
Dr. Miura has nothing to disclose.

5:30 PM 091 Clinical challenges in rapidly progressive dementia:lessons learned from an autopsy series Andrew Natonson, MD
Disclosure:
Dr. Natonson has nothing to disclose.

5:30 PM 092 Neuropathological correlates of apathy in Alzheimer’s disease Wendy Chen, MD
Disclosure:
Dr. Chen has nothing to disclose.

Vascular Disease and Dementia
Start Time Pub. Title Presenter
5:30 PM 093 Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer’s Disease Neuropathology in 1,421 Participants from the National Alzheimer’s Coordinating Center Neuropathology Data Set Jonathan Duskin
Disclosure:
Dr. Duskin has nothing to disclose.

5:30 PM 094 High Pulse Pressure and Hypertension are Independently Associated with Cognitive Impairment in Early Untreated Parkinson's Disease Maxime Doiron
Disclosure:
Dr. Doiron has nothing to disclose.

5:30 PM 095 Early Diagnosis of Vascular Cognitive Impairment Leads to Improved Treatment of Vascular Risk Factors Angelia Kirkpatrick
Disclosure:
Dr. Kirkpatrick has nothing to disclose.

5:30 PM 096 Neurofilament light chain as a serum marker for cerebral small vessel disease Marco Duering
Disclosure:
Dr. Duering has nothing to disclose.

5:30 PM 097 White matter microstructure in the DMN mediates the effects of aging, Alzheimer's, and cerebrovascular pathology on executive function Christopher Brown
Disclosure:
Dr. Brown has nothing to disclose.

5:30 PM 098 Predicting long term cognitive outcomes after stroke using pre and post-stroke cognitive trajectories. Neil Thomas, MD
Disclosure:
Dr. Thomas has nothing to disclose.

5:30 PM 099 Impact of co-morbid amyloid pathology on clinical phenotype of patients with vascular cognitive impairment David Bergeron
Disclosure:
Dr. Bergeron has nothing to disclose.

5:30 PM 100 NA NA NA
Disclosure:

MS and CNS Inflammatory Disease Poster Discussion Session
Start Time Pub. Title Presenter
5:30 PM 101 Long-term exposure to natalizumab during pregnancy – a prospective case series from the German Multiple Sclerosis and Pregnancy Registry Kerstin Hellwig
Disclosure:
Dr. Hellwig has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with speaker honoraria: Biogen Idec, Teva, Sanofi Aventis, Novartis, Bayer Healthcare, Merck Serono.

5:30 PM 102 EVOLVE-MS-1: Phase 3 Open-Label Long-Term Safety Study of ALKS 8700 in Relapsing-Remitting Multiple Sclerosis Robert Naismith
Disclosure:
Dr. Naismith has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Alkermes, Bayer, Biogen, EMD Serono, Genentech, Genzyme, Novartis, and Teva. Dr. Naismith has received personal compensation in an editorial capacity for NEJM Journal Watch.

5:30 PM 103 Outcomes of the TOPIC Extension Study of Teriflunomide in Patients With Early Multiple Sclerosis: Up to 7 Years of Clinical Results Aaron E Miller
Disclosure:
Dr. Miller has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Accordant Health Services (Caremark), Adama, BiogenIdec, Celgene, Genzyme/Sanofi, Mallinckrodt, Mapi-Pharma, Novartis, and Roche/Genentech. Dr. Miller has received personal compensation in an editorial capacity for Continuum Audio. Dr. Miller has received research support from BiogenIdec, Genzyme/Sanofi, Mallickrodt, Novartis, Roche/Genentech, and MedDay.

5:30 PM 104 Alemtuzumab Durably Slows Brain Volume Loss Over 6 Years in the Absence of Continuous Treatment in Patients With Active RRMS Who Were Treatment-Naive (CARE-MS I) or Had an Inadequate Response to Prior Therapy (CARE-MS II) Anthony Traboulsee, MD
Disclosure:
Dr. Traboulsee has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Chugai, F. Hoffmann-La Roche Ltd, Novartis, Sanofi Genzyme and Teva. Dr. Traboulsee has received research support from F. Hoffmann-La Roche Ltd.

5:30 PM 105 Clinical and Radiographic Correlations in Patients with Brain Biopsy-Confirmed Tumefactive Demyelination Matthew Tremblay
Disclosure:
Dr. Tremblay has nothing to disclose.

5:30 PM 106 DPPX-antibody associated encephalitis: main syndrome and antibody effects Makoto Hara
Disclosure:
Dr. Hara has nothing to disclose.

5:30 PM 107 Exploratory MRI Biomarkers of Opicinumab (Anti-LINGO-1) Show Stabilization of Pre-existing T2 Lesions in Relapsing Multiple Sclerosis: Results from the Phase 2b SYNERGY Trial Karleyton C. Evans, MD
Disclosure:
Dr. Evans has received personal compensation for activities with Biogen Idec as an employee. Dr. Evans holds stock and/or stock options in Biogen Idec.

5:30 PM 108 Comparison of blood lymphocyte counts and reported rates of infection in patients treated with fingolimod and iDMTs in PREFERMS Edward Fox, MD, PhD, FAAN
Disclosure:
Dr. Fox has nothing to disclose.

5:30 PM 109 Neuroanatomical Correlates of Memory and Speed are Dissociable in Multiple Sclerosis James Sumowski
Disclosure:
Dr. Sumowski has nothing to disclose.

5:30 PM 110 Pregnancy Complications of Women With and Without Multiple Sclerosis in a Large US Claims Database Maria K. Houtchens, MD
Disclosure:
Dr. Houtchens has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme Sanofi, Teva Neurosciences, Biogen, and Genentech. Dr. Houtchens has received research support from Genzyme Sanofi, Biogen, and Serono.

Myopathies and Myasthenia Gravis II
Start Time Pub. Title Presenter
5:30 PM 111 Frequency and duration of electrical myotonia as biomarkers of myotonia congenita Samantha LoRusso, MD
Disclosure:
Dr. LoRusso has received research support from Catalyst.

5:30 PM 112 Camptocormia with Anti Ku antibodies in Inclusion Body Myositis William Jens, DO
Disclosure:
Dr. Jens has nothing to disclose.

5:30 PM 114 Congenital myasthenic syndrome presenting in the sixth decade. Bernadette Monaghan, MD
Disclosure:
Dr. Monaghan has nothing to disclose.

5:30 PM 115 Vitamin Deficiencies in Patients with Myopathies and Other Neuromuscular Conditions Dubravka Dodig, MD
Disclosure:
Dr. Dodig has received personal compensation from Sanofi Genzyme as a speaker.

5:30 PM 116 A case of concurrent AL-amyloidosis with transthyretin c.371G>A/p.R124H polymorphism treated with autologous stem cell transplantation for 3 years. Sleiman El Jamal, MD
Disclosure:
Dr. El Jamal has nothing to disclose.

5:30 PM 117 Dermatomyositis plus seronegative Lambert-Eaton myasthenic syndrome William Kean
Disclosure:
Dr. Kean has nothing to disclose.

5:30 PM 118 Health Utilities in Myasthenia Gravis Carolina Barnett Tapia, MD
Disclosure:
Dr. Barnett Tapia has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with CSL, UCB.

5:30 PM 119 Amyloid Myopathy Presenting with Dysphagia and an Inclusion Body Myositis Phenotype Ryan Jacobson, MD
Disclosure:
Dr. Jacobson has nothing to disclose.

5:30 PM 120 Beyond the Antibodies: Sera Metabolomic Biomarker Signatures Discriminate Myasthenic and Healthy Cohorts Derrick Blackmore
Disclosure:
Dr. Blackmore has nothing to disclose.

5:30 PM 121 Late-onset Pompe disease due to known and novel variants in GAA gene with possible contribution of a dystrophinopathy carrier state in a female patient. Eric Veloso
Disclosure:
Dr. Veloso has nothing to disclose.

5:30 PM 122 A Case of new onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma. Iyad Alnahhas
Disclosure:
Dr. Alnahhas has nothing to disclose.

5:30 PM 123 Post-exercise facilitation in a post-synaptic congenital myasthenic syndrome Stanley Iyadurai, MD, PhD
Disclosure:
Dr. Iyadurai has nothing to disclose.

5:30 PM 124 Intervention Effect on Fellow Muscle Biopsy Reading Accuracy in Inflammatory Myositis Anai Hamasaki, MD
Disclosure:
Dr. Hamasaki has nothing to disclose.

5:30 PM 125 Clinical Dermatomyositis Associated with Anti-HMG-CoA Reductase Antibody Positive Immune Mediated Necrotizing Myopathy: A Case Report Monica Lavian, DO
Disclosure:
Dr. Lavian has nothing to disclose.

5:30 PM 126 Atypical Presentation of CLCN1 Mutations: A Case Series Anisha Bhangav, MD
Disclosure:
Dr. Bhangav has nothing to disclose.

5:30 PM 127 Amyloid Myopathy as an Inclusion Body Myositis Mimic Anai Hamasaki, MD
Disclosure:
Dr. Hamasaki has nothing to disclose.

5:30 PM 128 Tongue abnormalities on Brain MRI in patients with neuromuscular disorders Chafic Karam, MD
Disclosure:
Dr. Karam has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with alnylam, alexion, sanofigenzyme,nufactor, soleohealth, and optioncare.

5:30 PM 129 A Rare Case of Asymptomatic Becker Muscular Dystrophy Fareed khan
Disclosure:
Dr. Khan has nothing to disclose.

5:30 PM 130 Molecular dysregulation of lipolysis and lipophagy in Lipid Storage Myopathies Corrado Angelini
Disclosure:
Dr. Angelini has nothing to disclose.

5:30 PM 131 Concentric exercise effects on skeletal muscle water T2 in Duchenne muscular dystrophy Ami Mankodi, MD
Disclosure:
Dr. Mankodi has nothing to disclose.

5:30 PM 132 Performance test evaluation of intra-rater and inter-rater reliability among examiners of histopathological findings in myositis subtypes Daniel Kimple, MD
Disclosure:
Dr. Kimple has nothing to disclose.

5:30 PM 133 Evaluation of Postural Control and Falls in Individuals with Myotonic Dystrophy Type 1 Katy Eichinger, PT, DPT, NCS
Disclosure:
Dr. Eichinger has nothing to disclose.

5:30 PM 134 Hereditary Myopathy with Early Respiratory Failure (HMERF) in an Afghan Woman: A Case Report Tim Lai, MD
Disclosure:
Dr. Lai has nothing to disclose.

5:30 PM 135 VCP Gene Mutation in a Veteran Presenting with Proximal Weakness Daniel Kimple, MD
Disclosure:
Dr. Kimple has nothing to disclose.

5:30 PM 136 Managing Myasthenia Gravis with Immunosuppressive Drugs: Lessons from the Patient Perspective Riaz Mahmood
Disclosure:
Dr. Mahmood has nothing to disclose.

5:30 PM 137 Necrotizing myopathy in two patients after the use of Moringa Simona Treidler, MD
Disclosure:
Dr. Treidler has nothing to disclose.

5:30 PM 138 Duration of Botox effects in Neuromuscular junction using single fiber EMG Elham Bayat, MD
Disclosure:
Dr. Bayat has nothing to disclose.

5:30 PM 139 Clinicodemographic Predictors of the Impact of Infections on Myasthenia Gravis Natalie Kukulka
Disclosure:
Dr. Kukulka has nothing to disclose.

5:30 PM 140 Identification of dysregulated musclin expression and elevated atrial natriuretic peptide levels in adult and congenital myotonic dystrophy. Donald McCorquodale, MD, PhD
Disclosure:
Dr. McCorquodale has nothing to disclose.

5:30 PM 141 Anti-PD1 Antibody Pembrolizumab treatment of Metastatic Thymic Cancer as Antigenic Trigger for Myasthenia Gravis Ahmareen Baten, MD
Disclosure:
Dr. Baten has nothing to disclose.

5:30 PM 142 Review of muscle biopsy technical safety and quality using a self-contained, vacuum-assisted biopsy technique Antonio Gallo, MD
Disclosure:
Dr. Gallo has nothing to disclose.

5:30 PM 143 Myofibrillar myopathy associated with DNAJB6 mutations Karthika Veerapaneni, MD
Disclosure:
Dr. Veerapaneni has nothing to disclose.

5:30 PM 144 NA NA NA
Disclosure:

5:30 PM 144 NA NA NA
Disclosure:

Headache: Basic and Clinical Science
Start Time Pub. Title Presenter
5:30 PM 145 Prolonged activation and sensitization of central trigeminovascular neurons by a single wave of CSD in male and female rats Agustin Melo-Carrillo
Disclosure:
Dr. Melo-Carrillo has nothing to disclose.

5:30 PM 146 Glutamate and Glutamine Distributions in Chronic Migraine: a Whole Brain MR Spectroscopy Study Teshamae Monteith, MD
Disclosure:
Dr. Monteith has nothing to disclose.

5:30 PM 147 Pharmacokinetic Modeling Study to Evaluate Two Intranasal Formulations of Sumatriptan for Nasal vs Gastrointestinal Tract Absorption Mary Lor
Disclosure:
Dr. Lor has nothing to disclose.

5:30 PM 149 Headache Version 2.0 Common Data Element (CDE) Recommendations: Update of the National Institute of Neurological Disorders and Stroke (NINDS) Headache CDEs Joy Esterlitz
Disclosure:
Dr. Esterlitz has nothing to disclose.

5:30 PM 150 Pain Induced Neurogenic Inflammation of the Meninges Zdravko Lackovic
Disclosure:
Dr. Lackovic has nothing to disclose.

5:30 PM 151 Metabolic signatures for migraine using NMR-based metabolomics Dong Jin Shin, MD
Disclosure:
Dr. Shin has nothing to disclose.

5:30 PM 152 Mechanisms underlying motion sickness and dizziness in migraine disorders Susan King
Disclosure:
Dr. King has nothing to disclose.

5:30 PM 153 Ocular and Cervical Vestibular Evoked Myogenic Potentials In Migraine HESNA BEKTAS
Disclosure:
Dr. BEKTAS has nothing to disclose.

5:30 PM 154 Magnetic resonance imaging in pediatric recurrent ophthalmoplegic cranial neuropathy Abdulla Alawadhi, MBBS
Disclosure:
Dr. Alawadhi has nothing to disclose.

5:30 PM 155 Rational Design of a Monoclonal Antibody (mAb) Inhibiting Calcitonin Gene-Related Peptide (CGRP), ALD403, Intended for the Prevention of Migraine Brian Baker
Disclosure:
Dr. Baker has received personal compensation for activities with Alder Bio Pharmaceuticals as an employee.

5:30 PM 156 Evaluating the Measurement Properties of a New Instrument- the Migraine Physical Function Impact Diary (MPFID) Ariane K. Kawata
Disclosure:
Dr. Kawata has received personal compensation for activities with Evidera as an employee.

5:30 PM 157 Challenges to Stakeholder Engagement in Population Headache Care in an Academic Health System Susan Baggaley
Disclosure:
Dr. Baggaley has received personal compensation for activities with Teva Neuroscience as a speaker. Dr. Baggaley's institution received an Independent Learning Grant for Change which was sponsored by Pfizer. Dr. Baggaley was a Principal Investigator on an unrestricted education grant looking at better Headache Treatment with use of Project ECHO model.

5:30 PM 158 Primary Headache Induced by the Valsalva Maneuver Is Associated with Cerebral Hyperemia due to Autoregulatory Failure. Peter Novak, MD
Disclosure:
Dr. Novak has nothing to disclose.

5:30 PM 159 What does the humanized monoclonal anti-CGRP antibody (TEV-48125) teach us about the perception of migraine headache? Agustin Melo-Carrillo
Disclosure:
Dr. Melo-Carrillo has nothing to disclose.

Headache: Clinical Trials and Therapeutics
Start Time Pub. Title Presenter
5:30 PM 160 Simultaneously Evaluating Treatment Differences in Mean Level and Consistency in Migraine Pain Intensity Using Location Scale Mixed Effects Modeling: Results from the COMPASS Study Richard B. Lipton, MD, FAAN
Disclosure:
Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Has reviewed for the NIA and NINDS, serves as consultant, advisory board member, or has received honoraria from: Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmit. Dr. Lipton has received royalty, license fees, or contractual rights payments from Receives royalties from Wolff’s Headache, 8th Edition, Oxford University Press, 2009 and Informa. Dr. Lipton holds stock and/or stock options in Holds stock options in eNeura Therapeutics and Biohaven. Dr. Lipton has received research support from Support from the NIH, the Migraine Research Foundation, the National Headache Foundation, Allergan plc, Amgen, Dr Reddy’s, and Novartis..

5:30 PM 161 Phase 1, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Erenumab (AMG 334) and Concomitant Sumatriptan on Blood Pressure in Healthy Subjects Jan de Hoon
Disclosure:
Dr. De Hoon has received personal compensation for activities with Ablynx, Merck Sharp & Dohme, Galderma, UCB, and Eli Lilly as an advisor and/or consultant. Dr. De Hoon has received research support from Amgen Inc., Abide, Galderma, Genentech, GSK, J&J, Merck Sharp & Dohme, and UCB.

5:30 PM 162 Greater occipital injection versus oral steroids for short term prophylaxis of cluster headache: a retrospective comparative study Jerry Wei
Disclosure:
Dr. Wei has nothing to disclose.

5:30 PM 163 Melatonin for Adolescent Migraine Prevention: A Pilot Internet-based Randomized Controlled Trial Amy Gelfand, MD
Disclosure:
Dr. Gelfand has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven, Eli Lilly, Zosano, and UpToDate. Dr. Gelfand has received personal compensation in an editorial capacity for JAMANeurology. Dr. Gelfand has received research support from eNeura. Dr. Gelfand's spouse has received funding from Genentech, MedDay and QuestDiagnostics.

5:30 PM 164 Hepatic safety of galcanezumab in patients with migraine: Results of three Phase 2 double-blind placebo-controlled trials Arie Regev
Disclosure:
Dr. Regev has received personal compensation for activities with Eli Lilly and Company as an employee. Dr. Regev holds stock and/or stock options in Eli Lilly and Company.

5:30 PM 165 75% responder rates provide improvement in HIT-6 scores from week 4 through 12 following a single infusion of ALD403, or placebo. Richard Lipton, MD, FAAN
Disclosure:
Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Has reviewed for the NIA and NINDS, serves as consultant, advisory board member, or has received honoraria from: Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmit. Dr. Lipton has received royalty, license fees, or contractual rights payments from Receives royalties from Wolff’s Headache, 8th Edition, Oxford University Press, 2009 and Informa. Dr. Lipton holds stock and/or stock options in Holds stock options in eNeura Therapeutics and Biohaven. Dr. Lipton has received research support from Support from the NIH, the Migraine Research Foundation, the National Headache Foundation, Allergan plc, Amgen, Dr Reddy’s, and Novartis..

5:30 PM 166 Comparing Average Level and Within-person Consistency in Clinical Disability Using AVP-825 vs. Sumatriptan Tablets: Applying Location Scale Mixed-effects Models Kenneth J. Shulman, DO
Disclosure:
Dr. Shulman has received personal compensation for activities with Avanir Pharmaceuticals, Inc. as an employee.

5:30 PM 167 Patient-Reported Outcomes in Patients with Chronic Migraine Receiving Placebo or Erenumab (AMG 334) in a Phase 2, Randomized, Double-Blind Study Stewart Tepper, MD
Disclosure:
Dr. Tepper has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Alder, Allergan, Amgen, ATI, Avanir, BioVison, Charleston Laboratories, Dr. Reddy’s, electroCore, eNeura, Eli Lilly, GLG, Guidepoint Global, Kimberly-Clark, Pernix, Pfizer, Scion Neurostim, Supernus, Teva, Zosano. Dr. Tepper has received personal compensation in an editorial capacity for American Headache Society. Dr. Tepper has received compensation for serving on the Board of Directors of ATI. Dr. Tepper has received research support from Alder, Allergan, Amgen, ATI, Avanir, Dr. Reddy’s, electroCore, eNeura, Scion Neurostim, Teva, Zosano.

5:30 PM 168 Introduction to Progressive Muscle Relaxation Therapy for Migraine in the Emergency Department: A Pilot Feasibility Study Mia Minen, MD
Disclosure:
Dr. Minen has nothing to disclose.

5:30 PM 169 Medical and Pharmacy Claims Analysis Comparing Outcomes with Extended-Release Topiramate (Trokendi XR®) and Immediate-Release Topiramate Welton O'Neal, PharmD
Disclosure:
Dr. O'Neal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Supernus Pharmaceuticals, Inc..

5:30 PM 170 Reduction in Chronic Migraine following Occipital Nerve Decompression Surgery: Further Implications for Extracranial Origin of Headache Pamela Blake MD, MD
Disclosure:
Dr. Blake, MD has nothing to disclose.

5:30 PM 171 Characterizing the Most Common AEs Following Treatment with AVP-825: Exploring Abnormal Taste and Nasal Discomfort Across Multiple Attacks in COMPASS Study James S. McGinley
Disclosure:
Dr. McGinley has received personal compensation for activities with Vector Psychometric Group, LLC. as an employee.

5:30 PM 172 Flunarizine for the Prophylaxis of Vestibular Migraine Natarajan Visvanathan, MD, DM
Disclosure:
Dr. Visvanathan has nothing to disclose.

5:30 PM 173 Posterior Hypothalamic Stimulation in Chronic Cluster Headache Jessika Thais da Silva Maia
Disclosure:
Dr. Nogueira Mendes Neto has nothing to disclose.

5:30 PM 174 Non-invasive vagus nerve stimulation for treatment of indomethacin-sensitive headaches Amy Tso
Disclosure:
Dr. Tso has nothing to disclose.

5:30 PM 175 Peripheral nerve blocks for the treatment of headache in older adults: a retrospective study Jacob Hascalovici
Disclosure:
Dr. Hascalovici has nothing to disclose.

5:30 PM 176 Effect on Verbal (Phonemic) Fluency and Patient Satisfaction in Chronic Migraine Patients Converted from Immediate-Release Topiramate (TPM-IR) to Extended-Release Topiramate (Trokendi XR®) John Rothrock, MD
Disclosure:
Dr. Rothrock has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Lilly, Amgen and Supernus.

5:30 PM 177 Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab Sheena Aurora
Disclosure:
Dr. Aurora has received personal compensation for activities with Eli Lilly and Company as an employee and Allergan as a consultant. Dr. Aurora hold stock and/or stock options in Lilly and Company.

5:30 PM 178 Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL Andrew Blumenfeld
Disclosure:
Dr. Blumenfeld has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Pernix, Teva, Avanir, Depomed, and Supernus. Dr. Blumenfeld has received royalty, license fees, or contractual rights payments from Allergan.

5:30 PM 179 Measures of functioning using MSQ v2.1 in patients with a history of episodic migraine and treated with galcanezumab or placebo injections in a Phase 2 clinical trial Janet Ford
Disclosure:
Dr. Ford has received personal compensation for activities with Eli Lily and Company as an employee. Dr. Ford has stock and/or stock options in Eli Lily and Company.

5:30 PM 180 Acceptability of Placebo in Cluster Headache Trials: A Patient Survey Melissa Rayhill, MD
Disclosure:
Dr. Rayhill has nothing to disclose.

General Neurology: Practice Improvement and Novel Approaches to Care
Start Time Pub. Title Presenter
5:30 PM 181 Post hospitalization follow-up clinic visits in neurological diseases Vamshi Balasetti, MD
Disclosure:
Dr. Balasetti has nothing to disclose.

5:30 PM 182 Utilization and Cost Savings of Neuroscience Telemedicine Clinic for State Prison Inmates Jennifer Majersik MD MS, MD
Disclosure:
Dr. Majersik has nothing to disclose.

5:30 PM 183 Feasibility of lumbar puncture in the presence of cerebral mass effect Krishna Kandregula
Disclosure:
Dr. Kandregula has nothing to disclose.

5:30 PM 184 Ask a Neurologist: What Primary Care Providers want to know, and the potential for reducing referrals through eConsults Ana Bradi, MD
Disclosure:
Dr. Bradi has nothing to disclose.

5:30 PM 185 Randomized Trial to Evaluate Optimal Recumbent Time after Lumbar Puncture Babar Khokhar, MD
Disclosure:
Dr. Khokhar has nothing to disclose.

5:30 PM 186 The path to specialist multidisciplinary care: A population based study of consultations, interventions and costs Miriam Galvin
Disclosure:
Dr. Galvin has nothing to disclose.

5:30 PM 187 Patterns of utilization of extracranial neurovascular ultrasound in patients with syncope in the context of the American Academy of Neurology (AAN) Choosing Wisely initiative. Jorge Ortiz-Garcia, MD
Disclosure:
Dr. Ortiz-Garcia has nothing to disclose.

5:30 PM 188 Diagnosis of Mitochondrial Diseases: Utility of a Clinical-molecular Approach Incorporating High Performance Sequencing Julieta Rosales
Disclosure:
Dr. Rosales has nothing to disclose.

5:30 PM 189 Analysis of Psychopharmacs and Potentially Inappropiated Medications Use in an Elderly Population Maria Bullrich
Disclosure:
Dr. Bullrich has nothing to disclose.

5:30 PM 190 The role of neurology in a medicine-based undiagnosed patient clinic: The Emory Special Diagnostic Clinic experience Joash T. Lazarus, MD
Disclosure:
Dr. Lazarus has nothing to disclose.

5:30 PM 191 Followup on Discrepant Clinical Signs among Patients with Organic Neurological Diseases Orwa Aboud, MD, PhD
Disclosure:
Dr. Aboud has nothing to disclose.

5:30 PM 192 Neurology At Your Fingertips Paola Mendez Gomez, MD
Disclosure:
Dr. Mendez Gomez has nothing to disclose.

5:30 PM 193 The neurology of noise: Musical therapy both path and present Nathan Carberry
Disclosure:
Dr. Carberry has nothing to disclose.

5:30 PM 194 Clinical Drug Development for Rare Disease in Neurology Bilal Abuasal
Disclosure:
Dr. Abuasal has nothing to disclose.

5:30 PM 195 Neurologic Complications Following Bariatric Surgery: A Case Report and Literature Review Mohamed Shehabeldin, MD
Disclosure:
Dr. Shehabeldin has nothing to disclose.

5:30 PM 196 A case of discrepancy between clinical and radiological findings in determination of brain death Vidita Khatri, MD
Disclosure:
Dr. Khatri has nothing to disclose.

5:30 PM 197 Impulse Control Disorders associated with Aripiprazole Farwa Ali, MD
Disclosure:
Dr. Ali has nothing to disclose.

5:30 PM 198 Catatonia Associated with Neurological Disorders: a Case Series Tamara Strohm, MD
Disclosure:
Dr. Strohm has nothing to disclose.

5:30 PM 199 Sexuality and disability, a poorly studied relationship in neurology Alejando Nasimbera
Disclosure:
Dr. Nasimbera has nothing to disclose.

5:30 PM 200 Levofloxacin Induced Dyschronometria Alexandra Weller
Disclosure:
Dr. Weller has nothing to disclose.

5:30 PM 201 Differential Diagnosis of MRI Corticospinal Tract Abnormalities Asya Wallach, MD
Disclosure:
Dr. Wallach has nothing to disclose.

5:30 PM 202 Development of an Algorithm for Treatment of Altered Mental Status in the Emergency Department Gabriel Moreno, MD
Disclosure:
Dr. Moreno has nothing to disclose.

General Neurology: Ataxia, Spasticity, and Gait Disorders
Start Time Pub. Title Presenter
5:30 PM 203 Cortical processing of tactile novelty detection in Friedreich ataxia Gilles Naeije
Disclosure:
Dr. Naeije has nothing to disclose.

5:30 PM 204 Adult Onset Opsoclonus Myoclonus Ataxia Syndrome Alejandro Kohler
Disclosure:
Dr. Kohler has nothing to disclose.

5:30 PM 205 An interesting differential for acute truncal ataxia Edouard Kamel, MD
Disclosure:
Dr. Kamel has nothing to disclose.

5:30 PM 206 Pattern reversal visual evoked potentials (prVEPs) in autosomal recessive hereditary spastic paraplegia with thin corpus callosum (ARHSPTCC) patients with SPG 11 mutations in Saudi Arabia Nouf Al-Faidi, MD
Disclosure:
Dr. Al-Faidi has nothing to disclose.

5:30 PM 207 An Unusual Tale of Falls: a Modern Mad Hatter Himmat Grewal, MBBS
Disclosure:
Dr. Grewal has nothing to disclose.

5:30 PM 208 A Case of Sensory Ataxia and Cardiac Hypertrophy Associated with Anti- Voltage Gated Potassium Channel (VGKC) Autoantibodies. Catherine Alessi
Disclosure:
Dr. Alessi has nothing to disclose.

5:30 PM 209 A case of secondary parkinsonism responsive to Ibrutinib Erika Horta
Disclosure:
Dr. Horta has nothing to disclose.

5:30 PM 211 Subacute Cerebellar Degeneration due to Thiamine Deficiency after a Gastric Sleeve Rejo Cherian, MD
Disclosure:
Dr. Cherian has nothing to disclose.

5:30 PM 212 Dysphagia in a Patient with Fahr's Disease Jussie Lima, MD
Disclosure:
Dr. Lima has nothing to disclose.

General Neurology: Status Epilepticus and Critical Care
Start Time Pub. Title Presenter
5:30 PM 213 Mortality and clinical outcome of post cardiac arrest patients with refractory status epilepticus, Bashair Ibrahim
Disclosure:
Dr. Ibrahim has nothing to disclose.

5:30 PM 214 Riluzole-induced interstitial pneumonia: a rare and potentially life-threatening adverse event successfully treated with high-dose steroids. Yuji Saitoh
Disclosure:
Dr. Saitoh holds stock and/or stock options in Meiji Holdings Co., Ltd..

5:30 PM 215 Status Epilepticus and Blindness in a Patient with Carfilzomib Associated Posterior Reversible Encephalopathy Syndrome Scott Cooper
Disclosure:
Dr. Cooper has nothing to disclose.

5:30 PM 216 Postictal changes in brain magnetic resonance imaging: non convulsive status epilepticus in transplanted patients Alejandro Thomson
Disclosure:
Dr. Thomson has nothing to disclose.

5:30 PM 217 A rare case of CNS involvement with Chronic Lymphocytic Leukemia CLL Leslie Witton
Disclosure:
Dr. Witton has nothing to disclose.

5:30 PM 218 Refractory status epilepticus, report from a single center in Saudi Arabia Sohaib Shafei
Disclosure:
Dr. Shafei has nothing to disclose.

5:30 PM 219 Concurrent Duloxetine Withdrawal and Neuroleptic Malignant Syndrome Mimicking Creutzfeldt-Jakob Disease: A Case Report Emily Zucker
Disclosure:
Dr. Zucker has nothing to disclose.

5:30 PM 220 New onset epilepsy in the setting of middle fossa encephalocele and suspected idiopathic intracranial hypertension: a case report. Benjamin Savage, DO
Disclosure:
Dr. Savage has nothing to disclose.

5:30 PM 221 The number of Enteral Antiepileptic Drugs in Refractory Status Epilepticus: Their effect on patient mortality and clinical outcome Ruaa Nughays
Disclosure:
Dr. Nughays has nothing to disclose.

5:30 PM 222 NA NA NA
Disclosure:

Epilepsy and Clinical Neurophysiology: EEG and Imaging
Start Time Pub. Title Presenter
5:30 PM 223 The responsive neurostimulation (RNS) artifact on scalp EEG recording. Maria Jose Bruzzone Giraldez, MD
Disclosure:
Dr. Bruzzone has nothing to disclose.

5:30 PM 224 Application of sEMG Feature Extraction from EEG Recordings for Evaluation of Generalized Tonic-Clonic Seizure Semiology Jonathan Halford, MD
Disclosure:
Dr. Halford has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Brain Sentinel.

5:30 PM 225 Are automated topographic analyses of visual-evoked potentials reliable and feasible in clinical routine? Henrik Hörster
Disclosure:
Dr. Hörster has nothing to disclose.

5:30 PM 226 Generalized Paroxysmal Fast Activity in EEG: not an uncommon finding in genetic generalized epilepsy Vishwanath Sagi
Disclosure:
Dr. Sagi has nothing to disclose.

5:30 PM 227 Adjunctive Monitoring with Quantitative EEG During Carotid Endarterectomy Brad Kamitaki, MD
Disclosure:
Dr. Kamitaki has nothing to disclose.

5:30 PM 228 Utility of SSEP and EEG as prognostic indicators in patients with postanoxic injury with and without hypothermia. Advait Mahulikar
Disclosure:
Dr. Mahulikar has nothing to disclose.

5:30 PM 229 Multistate Survival Analysis for Seizure Prediction on Continuous EEG Aaron Struck, MD
Disclosure:
Dr. Struck has nothing to disclose.

5:30 PM 230 Abnormalities in Routine Clinical EEG Reports are Correlated with Delirium Severity Anudeepthi Neelagiri
Disclosure:
Dr. Neelagiri has nothing to disclose.

5:30 PM 231 Oscillation alterations by hippocampal interictal discharges as a mechanism of transient cognitive impairment Jonathan Kleen, MD, PhD
Disclosure:
Dr. Kleen has nothing to disclose.

5:30 PM 232 Electroencephalogram characteristics in cooled and re-warmed periods in post-cardiac arrest therapeutic hypothermia patients Kyung-Wha Kim, MD
Disclosure:
Dr. Kim has nothing to disclose.

5:30 PM 233 Common etiologies of acute symptomatic seizures evolving from lateralized periodic discharges in patients monitored with continuous EEG Subin Mathew, MD
Disclosure:
Dr. Mathew has nothing to disclose.

5:30 PM 234 The effects of perampanel, lacosamide, and lamotrigine on secondary generalized (SG) seizures in a rat amygdala kindling model Wu Ting
Disclosure:
Dr. Ting has received personal compensation for activities with Eisai as an employee.

5:30 PM 235 Use of functional cortical networks model for the assessment of transcranial direct current stimulation effects Camila Cosmo, MD, PhD
Disclosure:
Dr. Cosmo has nothing to disclose.

5:30 PM 236 The evolution of EEG in the disease course of NMDA-receptor encephalitis: 2 illustrative case studies and a review of the literature Claude Steriade, MD
Disclosure:
Dr. Steriade has nothing to disclose.

5:30 PM 237 Larger amygdala volumes in patients with "Sudden Unexpected Death in Epilepsy" Varun Chauhan, MD
Disclosure:
Dr. Chauhan has nothing to disclose.

5:30 PM 238 Clinical utility and validity of ictal EEG source localization in presurgical workup of neocortical epilepsy Deanne Kennedy
Disclosure:
Dr. Kennedy has nothing to disclose.

5:30 PM 239 Semantic fluency impairment in unilateral mesial temporal sclerosis related epilepsy is associated with extensive white matter involvement: a diffusion tensor imaging study. Matheus Peres
Disclosure:
Dr. Peres has nothing to disclose.

5:30 PM 240 Cortical Thickness Correlates of Social Cognition Abilities in Temporal Lobe Epilepsy Jeffrey Binder
Disclosure:
Dr. Binder has nothing to disclose.

5:30 PM 241 White matter tracts integrity in children with focal cortical dysplasia Sabrina Gouvêa
Disclosure:
Dr. Gouvêa has nothing to disclose.

5:30 PM 242 Periictal MRI findings of hypervascularity with restricted diffusion contralateral to gaze deviation Rita Marshall, MD
Disclosure:
Dr. Marshall has nothing to disclose.

Epilepsy and Clinical Neurophysiology: Clinical Epilepsy II
Start Time Pub. Title Presenter
5:30 PM 243 Electrophysiological and radiological characteristics in posterior reversible encephalopathy syndrome (PRES) Riddhi Patira, MD
Disclosure:
Dr. Patira has nothing to disclose.

5:30 PM 244 EEG correlates of outcome in patients with posterior reversible encephalopathy syndrome Archana Hinduja, MD
Disclosure:
Dr. Hinduja has nothing to disclose.

5:30 PM 245 Rates and Predictors of 1 year of Readmission with Seizures in Patients with Stroke and Stroke Subtypes: Analysis of a National Cohort of 557,033 Stroke Patients Burhan Chaudhry, MD
Disclosure:
Dr. Chaudhry has nothing to disclose.

5:30 PM 246 Adult-Onset Rasmussen's Encephalitis: Diagnostic and Therapeutic Challenges James Castellano
Disclosure:
Dr. Castellano has nothing to disclose.

5:30 PM 247 Incidence of unprovoked seizures, epilepsies, and epilepsy syndromes in a cohort of children accessing government primary schools and organization of seizures and epilepsies using ILAE 2010 system: A study in south India Shyam K Jaiswal
Disclosure:
Dr. Jaiswal has nothing to disclose.

5:30 PM 248 Epilepsy Awareness in a South Florida community – an observational study Subin Mathew, MD
Disclosure:
Dr. Mathew has nothing to disclose.

5:30 PM 249 Recurrent Seizure-related Takotsubo Syndrome Yuri Bronstein, MD
Disclosure:
Dr. Bronstein has nothing to disclose.

5:30 PM 250 NA NA NA
Disclosure:

Intracerebral Hemorrhage
Start Time Pub. Title Presenter
5:30 PM 251 Intraventricular hemorrhage score and outcome after spontaneous intracerebral hemorrhage Gabriela Trifan, MD
Disclosure:
Dr. Trifan has nothing to disclose.

5:30 PM 253 What are the barriers for use of pharmacological prophylaxis (PP) to prevent deep vein thrombosis (DVT) in spontaneous intracranial bleeding (sICH)? Dilip Kumar Jayaraman
Disclosure:
Dr. Jayaraman has nothing to disclose.

5:30 PM 254 Clinical outcomes of methamphetamine use in patients presenting with intracerebral hemorrhage Dionne Swor, DO
Disclosure:
Dr. Swor has nothing to disclose.

5:30 PM 255 Effect Of Insufficient Blood Pressure Control On Intracerebral Hemorrhage Volume In Patients Transferred To A Comprehensive Stroke Center Steven Tversky
Disclosure:
Dr. Tversky has nothing to disclose.

5:30 PM 256 Intraventricular Hemorrhage (Graeb) Score Predicts Prognosis in Lobar and Thalamic Intracerebral Hemorrhage Amanda Pennington, MD
Disclosure:
Dr. Pennington has nothing to disclose.

5:30 PM 257 Hyperosmolar therapy is not associated with improved outcomes in patients with large Intracerebral Hemorrhage. Shaista Alam, MD
Disclosure:
Dr. Alam has nothing to disclose.

5:30 PM 258 Long Term Functional Outcome and Mortality in Elderly Patients After Intracerebral Hemorrhage Audrey Leasure
Disclosure:
Dr. Leasure has nothing to disclose.

5:30 PM 259 To study the impact of chronic vasodilator therapy on perihematomal edema in primary intracerebral hemorrhage(ICH) Mini Singh, MD
Disclosure:
Dr. Singh has nothing to disclose.

5:30 PM 260 Transcranial Doppler Utilization in Non-Traumatic Intracerebral Hemorrhage: A Nationwide Cross-Sectional Analysis of Predictors and Outcomes. Abhishek Lunagariya, MD
Disclosure:
Dr. Lunagariya has nothing to disclose.

5:30 PM 261 A Comparison of Age, Gender, and Initial Blood Pressure between Hispanic and Non-Hispanic Intracerebral Hemorrhage Patients Lauren Fanty
Disclosure:
Dr. Fanty has nothing to disclose.

5:30 PM 262 Perihematomal Edema is Associated with Poor Outcome in Patients with Cerebellar Intracerebral Hemorrhage Audrey Leasure
Disclosure:
Dr. Leasure has nothing to disclose.

5:30 PM 263 Exploring the worth of CTA for ICHUsefulness of CT Angiography in the Diagnosis and Treatment of Intracranial Hemorrhage Abdul Rahman Alchaki, MD
Disclosure:
Dr. Alchaki has nothing to disclose.

5:30 PM 264 The role of a history of coronary artery disease, the need for transfusion and outcomes in patients with intracerebral hemorrhage Ayaz Khawaja, MD
Disclosure:
Dr. Khawaja has nothing to disclose.

5:30 PM 265 Does Race Predict Surgical Feeding Tube Placement In Intracerebral Hemorrhage? Aurangzeb Memon, MBBS
Disclosure:
Dr. Memon has nothing to disclose.

5:30 PM 266 Utilization of Modified SPAN-100 index in Patients with Intracerebral Hemorrhage: Predictor of Outcomes and Functionality Cyrus Escabillas, MD
Disclosure:
Dr. Escabillas has nothing to disclose.

5:30 PM 267 Clinical presentation and outcomes of young adults enrolled in the Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) Study Laura Miyares
Disclosure:
Dr. Miyares has nothing to disclose.

5:30 PM 268 Diagnostic yield of brain MRI in patients presenting with spontaneous intracerebral hemorrhage Andrew Slusher, MD
Disclosure:
Dr. Slusher has nothing to disclose.

5:30 PM 269 Foley Catheter Use and Infection in Non-Intubated Intracerebral Hemorrhage Patients Elena Gibson
Disclosure:
Dr. Gibson has nothing to disclose.

5:30 PM 270 Intra-hematomal hypodensity detected by computed tomography and risk of hemorrhage expansion in spontaneous intracerebral hemorrhage Joshua VanDerWerf, MD
Disclosure:
Dr. VanDerWerf has nothing to disclose.

5:30 PM 271 Infection is Not Associated with Poor Outcome in Young Adults with Hemorrhagic Stroke Kathryn Sundheim
Disclosure:
Dr. Sundheim has nothing to disclose.

5:30 PM 273 Resumption of Antithrombotic Therapy in LVAD-associated Intracranial Hemorrhages Sung-Min Cho, DO
Disclosure:
Dr. Cho has nothing to disclose.

5:30 PM 274 Neuroimaging Characteristics of Intracranial Hemorrhages and Microhemorrhages in Infective Endocarditis Lucy Zhang, MD
Disclosure:
Dr. Zhang has nothing to disclose.

5:30 PM 275 Off-Hours Emergency Department Arrival Does Not Result in Poor Outcomes Among Intracerebral Hemorrhage Patients Admitted to a Comprehensive Stroke Center Sahil Gupta, MD
Disclosure:
Dr. Gupta has nothing to disclose.

5:30 PM 276 Systematic Review and Meta-Analysis of Cohort Studies Examining Effect of Anticoagulation and Risk of Cerebral Hemorrhage in patients with Cerebral Microbleeds Nida Faheem, MD
Disclosure:
Dr. Faheem has nothing to disclose.

5:30 PM 277 Diagnostic yield of computed tomography angiography and cerebral angiography in patients with acute spontaneous intracerebral hemorrhage Alejandro Santillan, MD
Disclosure:
Dr. Santillan has nothing to disclose.

5:30 PM 278 Headache as an Independent Predictor of Favorable Outcome in Older Intracerebral Hemorrhage Patients Sahil Gupta, MD
Disclosure:
Dr. Gupta has nothing to disclose.

5:30 PM 279 Could Cocaine Exposure Mitigate Edema Formation in Spontaneous Intracerebral Hemorrhage? Mini Singh, MD
Disclosure:
Dr. Singh has nothing to disclose.

Subarachnoid Hemorrhage, Intracranial Aneurysm, and Other Cerebrovascular Malformations
Start Time Pub. Title Presenter
5:30 PM 280 Dynamic Response of Neuronal Activity to Mean Arterial Pressure and Neurocritical Interventions Measured by Intracranial EEG following Subarachnoid Hemorrhage Apeksha Shenoy
Disclosure:
Dr. Shenoy has nothing to disclose.

5:30 PM 281 The Temporospatial Role of Microcirculatory Dysfunction in the Prediction of Ischemia or Infarction in Patients with Aneurysmal Subarachnoid Hemorrhages Arelys Zamora, MD
Disclosure:
Dr. Zamora has nothing to disclose.

5:30 PM 283 MR Perfusion predicts angiographic vasospasm after aneurysmal subarachnoid hemorrhage Kassi Kronfeld, MD
Disclosure:
Dr. Kronfeld has nothing to disclose.

5:30 PM 284 Quantitative EEG spectral categories related to corticothalamic integrity and short-term clinical outcomes after aneurysmal subarachnoid hemorrhage – an exploratory analysis Peter Forgacs, MD
Disclosure:
Dr. Forgacs has nothing to disclose.

5:30 PM 285 Safety of Eptifibatide in Subarachnoid Hemorrhage Patients Requiring Antiplatelet Agents. Siddhart Mehta, MD
Disclosure:
Dr. Mehta has nothing to disclose.

5:30 PM 286 Reversible Cerebral Vasoconstriction Syndrome presenting as Convexity Subarachnoid Hemorrhage Rachel Forman, MD
Disclosure:
Dr. Forman has nothing to disclose.

5:30 PM 287 Torsades de Pointes as a Late Complication of Subarachnoid Hemorrhage Kyle Carpenter, DO
Disclosure:
Dr. Carpenter has nothing to disclose.

5:30 PM 288 Comparison of Pipeline Embolization Device With Conventional Endovascular Procedures For The Treatment Of Carotid Cavernous Aneurysms N Aij
Disclosure:
Dr. Aij has nothing to disclose.

5:30 PM 289 Delayed Onset Transient Pupillary Involving Third Cranial Nerve Palsy in Perimesencephalic Nonaneurysmal Subarachnoid Hemorrhage Lesley Kaye, MD
Disclosure:
Dr. Kaye has nothing to disclose.

5:30 PM 290 The Evaluation of the Treatment of Ruptured Intracranial Aneurysms with Pipeline Embolization Device. N Aij
Disclosure:
Dr. Aij has nothing to disclose.

5:30 PM 292 Trends and Predictors of Utilization of Endovascular Coiling vs Microsurgical Clipping of Ruptured Intracranial Aneurysms Vamshi Balasetti, MD
Disclosure:
Dr. Balasetti has nothing to disclose.

5:30 PM 293 Does the unruptured intracranial aneurysm treated score (UIATS) have a high risk of rupture threshold? Mohtashim Qureshi
Disclosure:
Dr. Qureshi has nothing to disclose.

5:30 PM 294 Intra-Operative Neurophysiologic Monitoring for Brain Aneurysm Surgeries in the United States: national use and outcomes Leila Darki
Disclosure:
Dr. Darki has nothing to disclose.

5:30 PM 295 Endovascular treatment of pediatric intracranial aneurysms: A systematic review and meta-analysis Brandon Bond, MD, MPH
Disclosure:
Dr. Bond has nothing to disclose.

5:30 PM 296 The Characteristics of Infectious Intracranial Aneurysm and Indication of Cerebral Angiogram in Infective Endocarditis Sung-Min Cho, DO
Disclosure:
Dr. Cho has nothing to disclose.

5:30 PM 297 A Rare Association of Vertebrobasilar Territory Arterial Fenestration with Aneurysm And Arteriovenous Malformation Asma Malik, MD
Disclosure:
Dr. Malik has nothing to disclose.

5:30 PM 298 Multiple Acute Ischemic Strokes due to Cerebral AVM Vascular Steal Phenomenon Nirav Bhatt, MD
Disclosure:
Dr. Bhatt has nothing to disclose.

5:30 PM 299 Two-Year Observational Study of Deferiprone in Superficial Siderosis Remi Kessler
Disclosure:
Dr. Kessler has nothing to disclose.

5:30 PM 300 Hospital utilization, length stay and inhospital mortality in patients with subarachnoid hemorrhage among different racial groups Alberto Maud, MD
Disclosure:
Dr. Maud has nothing to disclose.

HIV, HTLV-I, PML, Other Viral Infections, and CJD
Start Time Pub. Title Presenter
5:30 PM 301 Prevalence of Neurocognitive Disorders in a Well-treated and Aging Swiss HIV-cohort Mélanie Métral
Disclosure:
Dr. Métral has nothing to disclose.

5:30 PM 302 Cognitive function in newly diagnosed patients with HIV infection in a Nigerian Tertiary Health Centre: assessment using Community Screening Interview for Dementia Taofiki Sunmonu, MD
Disclosure:
Dr. Sunmonu has nothing to disclose.

5:30 PM 303 Sensitivity and Specificity of Three Screening Questions for Cognitive Disorders Mélanie Métral
Disclosure:
Dr. Métral has nothing to disclose.

5:30 PM 304 Prominent motor abnormalities in Thai men and women with presumed subtype CRF01_AE HIV-1 infection improve with antiretroviral therapy Andrew Silverman
Disclosure:
Dr. Silverman has nothing to disclose.

5:30 PM 305 Motor neuron disease in patients with HIV infection Paulo Lorenzoni, MD
Disclosure:
Dr. Lorenzoni has nothing to disclose.

5:30 PM 306 NMDAR-Encephalitis Masquerading as Recurrent HIV-Encephalitis with CSF escape in an HIV+ Patient C. Frances Fan
Disclosure:
Dr. Fan has nothing to disclose.

5:30 PM 307 AIDS-associated upper motor neuron disease with unique radiographic findings Johannes Pulst-Korenberg, MD
Disclosure:
Dr. Pulst-Korenberg has nothing to disclose.

5:30 PM 308 Solitary Cerebral Tumefactive Demyelinating Lesion in HIV: A case report Natalie Manalo
Disclosure:
Dr. Manalo has nothing to disclose.

5:30 PM 309 Longitudinally Extensive Transverse Myelitis (LETM) related to Human T-Cell Lymphotropic Virus 1 and 2 (HTLV-1/2): surprising clinical picture and neuroimaging findings Bianca Aleixo, MD
Disclosure:
Dr. Aleixo has nothing to disclose.

5:30 PM 310 Successful Treatment of HTLV-1 Associated Myelopathy with Chronic Immunosuppression Alessandro Iliceto
Disclosure:
Dr. Iliceto has nothing to disclose.

5:30 PM 311 Herpes simplex virus 2: a rare cause of ascending encephalomyelitis Tigran Kesayan, MD
Disclosure:
Dr. Kesayan has nothing to disclose.

5:30 PM 312 Fatal VZV Myelitis In Association With Chronic Corticosteroid and Mycophenolate Mofetil Therapy C. Chauncey Spears, MD
Disclosure:
Dr. Spears has nothing to disclose.

5:30 PM 313 Isolated seizures complicating influenza A and B infection in healthy adults Juan Garcia Monco, MD, FAAN
Disclosure:
Dr. Garcia Monco Carra has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulted for Allergan plc.

5:30 PM 314 Adult Onset Opsoclonus-myoclonus Ataxia Syndrome due to West Nile Virus: Two case reports Kenny Tan
Disclosure:
Dr. TAN has nothing to disclose.

5:30 PM 315 An Unusual Presentation of Varicella Zoster Virus with Acute Cerebellitis and SIADH without a rash. Michal Lubomski, MBBS
Disclosure:
Dr. Lubomski has nothing to disclose.

5:30 PM 316 Painful neuralgia of C2-3 followed by herpes zoster in the trigeminal nerve distribution Jinhyuk Yoo
Disclosure:
Dr. Yoo has nothing to disclose.

5:30 PM 317 Fatal Atypical Progressive Multifocal Leukoencephalopathy (PML) in an African American Female with Sarcoidosis Associated Lymphopenia (SAL). A Rare Case Report and Literature Review. Jaivir Rathore, MD
Disclosure:
Dr. Rathore has nothing to disclose.

5:30 PM 318 Immunosenescence and the importance of age in risk stratification of progressive multifocal leukoencephalopathy Elena Grebenciucova
Disclosure:
Dr. Grebenciucova has nothing to disclose.

5:30 PM 319 PML in the absence of HIV or immunosuppressive therapy Stacy Chu, MD
Disclosure:
Dr. Chu has nothing to disclose.

5:30 PM 320 Resurgence of Polio? Modern day Epidemic Nikil Swamy, MD
Disclosure:
Dr. Swamy has nothing to disclose.

5:30 PM 321 Synergistic drug combination effectively blocks Ebola virus infection Omid Motabar, MD
Disclosure:
Dr. Motabar has nothing to disclose.

5:30 PM 322 A Case of Post-EBV Cerebellitis Treated with IVIG Ugur Sener, MD
Disclosure:
Dr. Sener has nothing to disclose.

5:30 PM 323 A Stormy Case of Rhinocerebral Mucormycosis, and A Recovery Against All Odds. Saman Zafar, MD
Disclosure:
Dr. Zafar has nothing to disclose.

Zika, Chikungunya, West Nile Virus, and Other Viral Infections I
Start Time Pub. Title Presenter
5:30 PM 324 Expanding Spectrum of Neurologic manifestations with Zika Virus Infection Laura Surillo Dahdah, MD
Disclosure:
Dr. Surillo Dahdah has nothing to disclose.

5:30 PM 325 Movement Disorder Development Later After Acute Disseminated Encephalomyelitis Associated with Zika Virus: Case Report Pamela Santos
Disclosure:
Dr. Santos has nothing to disclose.

5:30 PM 326 Probable Zika virus-associated Guillain-Barre syndrome: Challenges with clinico-laboratory diagnosi Zoe Becker
Disclosure:
Dr. Becker has nothing to disclose.

5:30 PM 327 Zika associated Guillain-Barre syndrome in the United States Gabriela Tantillo
Disclosure:
Dr. Tantillo has nothing to disclose.

5:30 PM 328 Case Report: A rare case of fatal disseminated Strongyloidiasis with central nervous system involvement in a White South Floridian HIV positive man Ima Ebong, MD
Disclosure:
Dr. Ebong has nothing to disclose.

Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, and Optic Neuritis I
Start Time Pub. Title Presenter
5:30 PM 329 Clinical Predictors of Death in Neuromyelitis Optica Spectrum Disorders Remi Kessler
Disclosure:
Dr. Kessler has nothing to disclose.

5:30 PM 330 Phase 1b clinical trial with antigen-specific tolerogenic dendritic in Multiple Sclerosis and Neuromyelitis optica: safety and immunological effects Irati Zubizarreta Nafarrate
Disclosure:
Dr. Zubizarreta Nafarrate has nothing to disclose.

5:30 PM 331 Different patterns of structural damage in neuromyelitis optica spectrum disorders, recurrent optic neuritis and recurrent myelitis Alessandro D'Ambrosio
Disclosure:
Dr. D'Ambrosio has nothing to disclose.

5:30 PM 332 Increased sensitivity of 2015 Neuromyelitis Optica Spectrum Disorder (NMOSD) diagnostic criteria in older, non-Asian subjects Karly Stratos
Disclosure:
Dr. Stratos has nothing to disclose.

5:30 PM 333 Microstructural changes in the afferent visual system of asymptomatic patients with AQP4-antibody positive neuromyelitis optica spectrum disorders. Frederike Oertel
Disclosure:
Dr. Oertel has nothing to disclose.

5:30 PM 334 An open-label, add-on trial of cetirizine for neuromyelitis optica Ilana Katz Sand, MD
Disclosure:
Dr. Katz Sand has nothing to disclose.

5:30 PM 335 Superficial Siderosis Masquerading as Neuromyelitis Optica Scott Belliston, DO
Disclosure:
Dr. Belliston has nothing to disclose.

5:30 PM 336 Steroid responsive anti-MOG antibody mediated meningo-encephalomyelitis and optic neuritis Melanie Truong, DO
Disclosure:
Dr. Truong has nothing to disclose.

5:30 PM 337 Quality of healthcare in patients with myelitis: A pilot study Valentina Galvis
Disclosure:
Dr. Galvis has nothing to disclose.

5:30 PM 338 Brain and spinal cord MRI findings in a South Florida cohort of Neuromyelitis Optica Spectrum Disorder patients Melissa Alberts
Disclosure:
Dr. Alberts has nothing to disclose.

5:30 PM 339 Is there a link between Neuro-Behcet’s Syndrome longitudinally extensive transverse myelitis and antibodies against MOG/AQP4 IgG? Aksel Siva, MD
Disclosure:
Dr. Siva has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Novartis, Teva, Genzyme, Bayer, Roche.

5:30 PM 340 Retinal Optical Coherence Tomography in Chronic Relapsing Inflammatory Optic Neuropathy: a retrospective analysis of distinctive features. Maziar Eslami, MD
Disclosure:
Dr. Eslami has nothing to disclose.

5:30 PM 341 What is the relationship of anti-MOG Antibodies with Optic Neuritis of Multiple Schlerosis and Neuromyelitis Optica? Fethi Idiman
Disclosure:
Dr. Idiman has nothing to disclose.

5:30 PM 342 A case of neuromyelitis optica spectrum disorder with a non-traumatic syringomyelia Shirley Nah
Disclosure:
Dr. Nah has nothing to disclose.

5:30 PM 343 Drug-abuse Related Myelopathies: A Rising Neurological Problem Gabriel Pinilla Monsalve
Disclosure:
Dr. Pinilla has nothing to disclose.

5:30 PM 344 A Rare Presentation of Neuromyelitis Optica Spectrum Disorder (NMOSD) with Headache and Abnormal Imaging Sahyli Perez Parra, MD
Disclosure:
Dr. Perez Parra has nothing to disclose.

Biomarkers and Experimental Studies for Multiple Sclerosis II
Start Time Pub. Title Presenter
5:30 PM 345 Extending lipid biomarkers of disease progression in people with multiple sclerosis Charlie Mckechnie
Disclosure:
Dr. Mckechnie has nothing to disclose.

5:30 PM 346 EBV Serological Status in Southeastern Spain. Possible Relation Between Clinical Activity and the Reactivation of the EBV Ester Carreón Guarnizo
Disclosure:
Dr. Carreon Guarnizo has nothing to disclose.

5:30 PM 347 Olfactory threshold predicts short term relapse activity in relapsing-remitting multiple sclerosis Gabriel Bsteh, MD
Disclosure:
Dr. Bsteh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Teva.

5:30 PM 348 Teriflunomide Impacts Primary Microglia and Astrocyte Functions In Vitro Andrea Edling
Disclosure:
Dr. Edling has received personal compensation for activities with Sanofi Genzyme as an employee.

5:30 PM 349 Progressive multiple sclerosis patients with NFKBIA mutations are less responsive to the immune changes induced by treatment with MIS416 Pamela McCombe, MD
Disclosure:
Dr. McCombe has nothing to disclose.

5:30 PM 350 Multimodal evoked potentials in primary progressive MS: A potential biomarker for prognosis and course Martin Hardmeier, MD
Disclosure:
Dr. Hardmeier has nothing to disclose.

5:30 PM 351 Intrathecal delivery of primary progressive MS cerebrospinal fluid induces behavioral deficits and spinal cord pathology in mice Jamie Wong
Disclosure:
Dr. Wong has nothing to disclose.

5:30 PM 352 CSF Biomarkers of Disease Progression in Patients with Multiple Sclerosis Shayna Zanker
Disclosure:
Dr. Zanker has nothing to disclose.

5:30 PM 353 Laquinimod modulates central nervous system inflammation via the aryl hydrocarbon receptor and is effective in the chronic NOD progressive EAE model Joel Kaye
Disclosure:
Dr. Kaye has received personal compensation for activities with Teva Pharmaceutical Industries Ltd. as an employee. Dr. Kaye holds stock and/or stock options in Teva Pharmaceutical Industries Ltd. Dr. Kaye has received research support from Teva Pharmaceuticals.

5:30 PM 354 Disability Progression and Cerebrospinal Fluid Status in PPMS: Re-Analysis of the ProMiSe Clinical Trial Data Set Joshua R Steinerman
Disclosure:
Dr. Steinerman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Teva.

5:30 PM 355 Laquinimod is a potent arylhydrocarbon receptor dependent activator of natural killer cells Erika Avendano-Guzman
Disclosure:
Dr. Avendano-Guzman has nothing to disclose.

5:30 PM 356 Kynurenine pathway profiling in phase 2a trial secondary progressive multiple Sclerosis patients treated with a myeloid directed innate immune modulator MIS416 Chai Lim
Disclosure:
Dr. Lim has nothing to disclose.

5:30 PM 357 Immunomodulatory effects of oral dimethyl fumarate on intestinal immune regulation during experimental autoimmune neuritis in Lewis rats Jeremias Motte
Disclosure:
Dr. Motte has received research support from Biogen idec.

5:30 PM 358 Cerebrospinal Fluid Biomarkers Associated with the Reparative Effects of Intrathecal MSC-NP Treatment in Patients with Progressive Multiple Sclerosis John Tuddenham
Disclosure:
Dr. Tuddenham has nothing to disclose.

5:30 PM 359 Low-dose Subcutaneous Anti-CD20 Therapy Effectively Depletes B Cells and Ameliorates Central Nervous System Autoimmunity Paul Smith
Disclosure:
Dr. Smith has received personal compensation for activities with Novartis Institutes of BioMedical Research as an employee.

5:30 PM 360 Odor identification is associated with neurodegeneration in relapsing-remitting multiple sclerosis Gabriel Bsteh, MD
Disclosure:
Dr. Bsteh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Teva.

5:30 PM 361 RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis Anat Achiron, MD, PhD
Disclosure:
Dr. Achiron has nothing to disclose.

5:30 PM 362 Novel Mechanism of Disease: Altered RNA metabolism due a dysfunctional RNA binding protein contributes to neurodegeneration in MS Michael Levin, MD, FAAN
Disclosure:
Dr. Levin has received personal compensation for activities with Serono, TEVA, Biogen-Idec, Gerson Lehman Group and The CME Institute as a consultant or speaker. Dr. Levin has received personal compensation in an editorial capacity for The Merck Medical Manual.

5:30 PM 363 Absences of HDAC3 and IL-33 in Neurons in Spinal Cord of Patients with Progressive Multiple Sclerosis Song-Yi Yao
Disclosure:
Dr. Yao has nothing to disclose.

5:30 PM 364 Localized over expression of FGF9 in the rat motor cortex reproduces the pathological features of grey matter lesions in progressive multiple sclerosis. Claudia Wrzos
Disclosure:
Dr. Wrzos has nothing to disclose.

5:30 PM 365 Laquinimod targets the aryl hydrocarbon receptor (AhR) pathway in periphery and brains of naive and EAE mice Tal Birnberg
Disclosure:
Dr. Birnberg has received personal compensation for activities with Teva Pharmaceutical Industries as an employee.

5:30 PM 366 Direct neuroprotective effect of laquinimod on glutamate excitotoxicity in experimental multiple sclerosis Francesca De Vito
Disclosure:
Dr. De Vito has nothing to disclose.

5:30 PM 367 Inhibition of myelination by FGF2 in the central nervous system is Wnt-dependent: implications for endogenous repair in multiple sclerosis. Katja Thuemmler
Disclosure:
Dr. Thuemmler has nothing to disclose.

5:30 PM 368 Immunization against CCL20, aTh17 cell related chemokine, may confer protection against multiple sclerosis (MS). Arnon Karni
Disclosure:
Dr. Karni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche, Stem cell Medicine. Dr. Karni has received research support from Merck, Sanofi.

5:30 PM 369 Xenogeneic assessment of mitochondrial bioenergetic impairment induced by CSF from MS patients Maureen Erwin
Disclosure:
Dr. Erwin has nothing to disclose.

CNS Inflammatory Diseases and Differential Diagnosis II
Start Time Pub. Title Presenter
5:30 PM 370 Intrathecal NMDA receptor antibody reactivation due new ovarian teratoma in patient with previously resected ovarian teratoma for anti-NMDA receptor encephalitis Hassaan Bashir, MBBS
Disclosure:
Dr. Bashir has nothing to disclose.

5:30 PM 371 CNS manifestations of voltage-gated calcium channel antibodies John Adair, MD
Disclosure:
Dr. Adair has nothing to disclose.

5:30 PM 372 Hemophagocytic Lymphohistiocytosis (HLH) / Macrophage Activated Syndrome (MAS) with CNS Aspergillus Jay Rosenberg MD
Disclosure:
Dr. Rosenberg has received personal compensation for activities with EMD Serona, Teva Pharma, and Mallinckrodt as a speaker.

5:30 PM 373 Tdap Vaccination and Acute Demyelinating Events Nicholas Gregg, MD
Disclosure:
Dr. Gregg has nothing to disclose.

5:30 PM 374 Hemorrhagic Acute Disseminated Encephalomyelitis (ADEM) as first Neuropsychiatric presentation of Systemic Lupus Erythematosus Gustavo Ribas
Disclosure:
Dr. Ribas has nothing to disclose.

5:30 PM 375 Fecal GABA levels are reduced in multiple sclerosis but not in neuro-Behcet disease Recai Turkoglu
Disclosure:
Dr. Turkoglu has nothing to disclose.

5:30 PM 376 Prodromal Stiffperson Syndrome: Two cases of antibody detection over a decade after symptom onset Amanda Piquet, MD
Disclosure:
Dr. Piquet has nothing to disclose.

5:30 PM 377 Tumefactive demyelinating lesions: Clinical and radiological features of 12 patients. Pedro Sánchez López
Disclosure:
Dr. Sánchez López has nothing to disclose.

5:30 PM 378 Giant-Cell Arteritis Presenting as Isolated Bilateral CN-VI Palsies: A Rare Case Report of a 65 Year Male. Abhishek Lunagariya, MD
Disclosure:
Dr. Lunagariya has nothing to disclose.

5:30 PM 379 Thalamic germinoma masquerading as CNS inflammatory disease: a case report Laura Baldassari, MD, MHS
Disclosure:
Dr. Baldassari has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva.

5:30 PM 380 Acute disseminated encephalomyelitis in China, Singapore, and Japan: a comparison with the U.S.A. Diederik Koelman
Disclosure:
Dr. Koelman has nothing to disclose.

5:30 PM 381 Histopathological neurosarcoidosis in response to disseminated seminoma with absence of central nervous system metastases Jennifer Massey, MBBS
Disclosure:
Dr. Massey has nothing to disclose.

5:30 PM 383 Adult Onset Hereditary Diffuse Leucoencephalopathy with Axonal Spheroids (HDLS): First Case Report in South America VERONICA ANALIA TKACHUK
Disclosure:
Dr. Tkachuk has nothing to disclose.

5:30 PM 384 Central nervous system demyelination in a patient with Cryopirin-Associated Periodic Syndrome treated with canakinumab Barbara Willekens, MD
Disclosure:
My institution received compensation for consultancy services, speaking, serving on advisory boards or travel support from Merck-Serono, Novartis, Teva, Roche, Biogen, Sanofi-Genzyme. . The institution received research support from Novartis for a project on multiple sclerosis and MRI. .

5:30 PM 385 Overlap of idiopathic and IgG4-related hypertrophic pachymeningitis: Case Series Uzma Usman, MD
Disclosure:
Dr. Usman has nothing to disclose.

5:30 PM 386 Glutamic Acid Decarboxylase Antibodies in Neurological Diseases: Validation of Enzyme-linked Immunosorbent Assay and Proposal of a Cut Off for Clinical Relevance Marco Zoccarato
Disclosure:
Dr. Zoccarato has nothing to disclose.

5:30 PM 387 CLIPPERS Syndrome in Association P/Q type Voltage Calcium Channel Antibody Michelle Devine
Disclosure:
Dr. Devine has nothing to disclose.

5:30 PM 388 MRI, Psychiatric and Neuropsychological Sequelae in Children with anti-NMDAR Encephalitis Lauren Sham, MD
Disclosure:
Dr. Sham has nothing to disclose.

5:30 PM 389 Neurosarcoidosis in a public safety net hospital: a study of 82 cases James Dorman, MD, FAAN
Disclosure:
Dr. Dorman has nothing to disclose.

5:30 PM 390 Neurologic and cranial manifestations of Erdheim-Chester disease Natalie Parks
Disclosure:
Dr. Parks has nothing to disclose.

5:30 PM 391 VGKC antibody testing in a tertiary referral center Grace Crotty, MD
Disclosure:
Dr. Crotty has nothing to disclose.

5:30 PM 392 A rare case of immune mediated meningoencephalitis presenting with bilateral ear swelling and progressive mental deterioration. Diana Londoño
Disclosure:
Dr. Londoño has nothing to disclose.

Discontinuation and Switching Disease Modifying Therapies in Multiple Sclerosis
Start Time Pub. Title Presenter
5:30 PM 393 Tolerability and Retention to Fingolimod in RRMS Patients who Switched from other Oral DMTs Yves Lapierre, MD
Disclosure:
Dr. Lapierre has received personal compensation for activities with Biogen Idec, Teva Canada, Sonofi-Genzyme, EMD Serono, Novartis, Roche for advisory boards. Dr. Lapierre has received personal compensation in an editorial capacity from Teva for serving as a member of an editorial board.

5:30 PM 394 Treatment Satisfaction Increased over One Year When MS Patients Switched from an Interferon Beta Therapy to Peginterferon Beta-1a Barry Hendin, MD, FAAN
Disclosure:
Dr. Hendin has received personal compensation for activities with Acorda, Biogen, EMD Serono, Genzyme, Mallinckrodt, Novartis, and Teva Neuroscience.

5:30 PM 395 Brain atrophy and lesion burden MRI trajectories after switch to natalizumab in multiple sclerosis patients Tomas Uher
Disclosure:
Dr. Uher has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with T. Uher received financial support for conference travel and honoraria from Biogen Idec, Novartis, Sanofi Genzyme, Roche, and Merck. Dr. Uher has received research support from Biogen Idec..

5:30 PM 396 Stable Multiple Sclerosis Patients on an Interferon Therapy Have Better Outcomes When Staying on Therapy Than Patients Who Switch to Another Interferon Chao Chen
Disclosure:
Dr. Chen has received personal compensation for activities with Biogen.

5:30 PM 397 Persistence with multiple sclerosis disease-modifying therapies is highest when switching to fingolimod compared with other oral and injectable therapies: a retrospective US claims database analysis Jonathan Korn
Disclosure:
Dr. Korn has received personal compensation for activities with QuintilesIMS.

5:30 PM 398 Effect of switching from daily injections of 20mg glatiramer acetate to 40mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis over 33 months Jesper Hagemeier
Disclosure:
Dr. Hagemeier has nothing to disclose.

5:30 PM 399 Real-World Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the Tysabri® Observational Program (TOP) Who Discontinued Natalizumab: Why They Stopped, Which Therapies They Switched To, and How Their Disease Activity Changed Maria Trojano
Disclosure:
Dr. Trojano has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Sanofi, Teva. Dr. Trojano has received research support from Biogen, Merck Serono, Novartis.

5:30 PM 400 Return of MS Disease Activity after Daclizumab Discontinuation Did Not Exceed Baseline Levels in SELECT/SELECTION Studies Gavin Giovannoni, MD
Disclosure:
Dr. Giovannoni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Almirall, Atara Bio, Biogen, Sanofi-Genzyme, Genentech, GSK, Merck, Novartis, Roche, and Teva. Dr. Giovannoni has received personal compensation in an editorial capacity for Elsevier as Editor of MSARDs. Dr. Giovannoni has received research support from Takeda.

5:30 PM 401 Disease Modifying Therapy Discontinuation in Patients with Multiple Sclerosis Over Age 60 Le H. Hua, MD
Disclosure:
Dr. Hua has nothing to disclose.

5:30 PM 402 Rebound of Multiple Sclerosis Disease Activity Following Fingolimod Cessation Afagh Garjani
Disclosure:
Dr. Garjani has nothing to disclose.

5:30 PM 403 Reducing Rebound Disease Activity in Relapsing Multiple Sclerosis Patients Electively Transitioned from Natalizumab to Teriflunomide Stanley Cohan, MD, PhD
Disclosure:
Dr. Cohan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employment, consulting, scientific advisory board, speaking, or other activities (Sanofi Genzyme, Biogen, Acorda, Genentech, Novartis). Advisory Boards, Research Steering Committees, Research Support and Speaking Honoraria, (Biogen, Mallinckrodt, Novartis. Dr. Cohan has received research support from Biogen, Mallinckrodt, Novartis, Roche Genentech, Sanofi Genzyme..

5:30 PM 405 Real-World Treatment Persistence Among Multiple Sclerosis Patients on Injectable Disease Modifying Therapies John Ko, PharmD, MS
Disclosure:
Dr. Ko has received personal compensation for activities with Novartis Pharmaceuticals Corporation as an employee.

5:30 PM 406 Effectiveness of Delayed-release Dimethyl Fumarate on Clinical Measures and Patient-Reported Outcomes in Relapsing Multiple Sclerosis (RMS) Patients Switching After Suboptimal Response to Glatiramer Acetate, Including Patients with Early MS: Subgroup Analysis of RESPOND Kiren Kresa-Reahl
Disclosure:
Dr. Kresa-Reahl has received personal compensation for activities with Biogen, EMD Serono, Genzyme, Novartis, Mallinckrodt, Teva, Genentech and EMD Serono as a consultant and/or speaker. Dr. Kresa-Reahl has received research support from Biogen, Genzyme, Mallinckrodt, and Novartis.

5:30 PM 407 High risk PML patients switching from natalizumab to alemtuzumab Antonio Bertolotto, MD
Disclosure:
Dr. Bertolotto has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Almirall, Biogen, Roche, Merck Serono, Novartis, Teva, Sanofi Genzyme, Mylan.

5:30 PM 408 Long-term natalizumab treatment enhances the pathogenic signature of Th17 cells – potential implications for treatment cessation? Claudia Janoschka
Disclosure:
Dr. Janoschka has nothing to disclose.

Medical Student Essay Award Recipients
Start Time Pub. Title Presenter
5:30 PM 409

Recycling endosomes mediate local, Golgi-independent secretory trafficking in neuronal dendrites

Aaron Bowen
Disclosure:

5:30 PM 410 Utility of an Electronic Customizable Sleep Behavioral Software Program "MySleepScript" in individuals with acquired brain injury Moon Jeong Lee
Disclosure:
Dr. Lee has nothing to disclose.

5:30 PM 411 Patients or Participants? The 1977 National Bioethics Commission and Multidisciplinary Oversight of "Innovative" Psychosurgery Bob Sun
Disclosure:

5:30 PM 412 Quantitative Comparison of K-D Balance and Sway Balance™ System Mobile Device Applications Chelsea Zhang
Disclosure:

Register Now

Related Courses